Search research articles
Contact Us
Filters
Showing results (51-60 of 54) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 54 results.
Medrxiv : the Preprint Server for Health Sciences
|
May 4, 2026
Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast Cancer
Frederick M Howard, Anran Li, Sara Kochanny, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 25, 2026
Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer Recurrence
Ngoc-Kim Nguyen, Anran Li, Sara Kochanny, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 5, 2025
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer
Frederick M Howard, James Dolezal, Hanna Hieromnimon, et al.
Nature Medicine
|
September 14, 2024
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 54) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 54 results.
Medrxiv : the Preprint Server for Health Sciences
|
May 4, 2026
Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast Cancer
Frederick M Howard, Anran Li, Sara Kochanny, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 25, 2026
Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer Recurrence
Ngoc-Kim Nguyen, Anran Li, Sara Kochanny, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 5, 2025
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer
Frederick M Howard, James Dolezal, Hanna Hieromnimon, et al.
Nature Medicine
|
September 14, 2024
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, et al.
Page
of 6